Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic Adults.

被引:1123
作者
Selvin, Elizabeth [1 ,2 ,4 ]
Steffes, Michael W. [5 ]
Zhu, Hong [3 ]
Matsushita, Kunihiro [2 ]
Wagenknecht, Lynne [7 ]
Pankow, James [6 ]
Coresh, Josef [2 ,3 ,4 ]
Brancati, Frederick L. [2 ,4 ]
机构
[1] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21287 USA
[2] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21287 USA
[3] Johns Hopkins Univ, Dept Biostat, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21287 USA
[4] Johns Hopkins Univ, Div Gen Internal Med, Dept Med, Baltimore, MD 21287 USA
[5] Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
[6] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55455 USA
[7] Wake Forest Univ, Bowman Gray Sch Med, Div Publ Hlth Sci, Winston Salem, NC USA
基金
美国国家卫生研究院;
关键词
CORONARY-HEART-DISEASE; ATHEROSCLEROSIS RISK; ENZYMATIC DETERMINATION; MORTALITY; A(1C); A1C; GLYCEMIA; CHOLESTEROL; MORBIDITY; OUTCOMES;
D O I
10.1056/NEJMoa0908359
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fasting glucose is the standard measure used to diagnose diabetes in the United States. Recently, glycated hemoglobin was also recommended for this purpose. Methods: We compared the prognostic value of glycated hemoglobin and fasting glucose for identifying adults at risk for diabetes or cardiovascular disease. We measured glycated hemoglobin in whole-blood samples from 11,092 black or white adults who did not have a history of diabetes or cardiovascular disease and who attended the second visit (occurring in the 1990-1992 period) of the Atherosclerosis Risk in Communities (ARIC) study. Results: The glycated hemoglobin value at baseline was associated with newly diagnosed diabetes and cardiovascular outcomes. For glycated hemoglobin values of less than 5.0%, 5.0 to less than 5.5%, 5.5 to less than 6.0%, 6.0 to less than 6.5%, and 6.5% or greater, the multivariable-adjusted hazard ratios (with 95% confidence intervals) for diagnosed diabetes were 0.52 (0.40 to 0.69), 1.00 (reference), 1.86 (1.67 to 2.08), 4.48 (3.92 to 5.13), and 16.47 (14.22 to 19.08), respectively. For coronary heart disease, the hazard ratios were 0.96 (0.74 to 1.24), 1.00 (reference), 1.23 (1.07 to 1.41), 1.78 (1.48 to 2.15), and 1.95 (1.53 to 2.48), respectively. The hazard ratios for stroke were similar. In contrast, glycated hemoglobin and death from any cause were found to have a J-shaped association curve. All these associations remained significant after adjustment for the baseline fasting glucose level. The association between the fasting glucose levels and the risk of cardiovascular disease or death from any cause was not significant in models with adjustment for all covariates as well as glycated hemoglobin. For coronary heart disease, measures of risk discrimination showed significant improvement when glycated hemoglobin was added to models including fasting glucose. Conclusions: In this community-based population of nondiabetic adults, glycated hemoglobin was similarly associated with a risk of diabetes and more strongly associated with risks of cardiovascular disease and death from any cause as compared with fasting glucose. These data add to the evidence supporting the use of glycated hemoglobin as a diagnostic test for diabetes. N Engl J Med 2010;362:800-11.
引用
收藏
页码:800 / 811
页数:12
相关论文
共 46 条
  • [21] Racial and Ethnic Differences in Mean Plasma Glucose, Hemoglobin A1c, and 1,5-Anhydroglucitol in Over 2000 Patients with Type 2 Diabetes
    Herman, William H.
    Dungan, Kathleen M.
    Wolffenbuttel, Bruce H. R.
    Buse, John B.
    Fahrbach, Jessie L.
    Jiang, Honghua
    Martin, Sherry
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (05) : 1689 - 1694
  • [22] Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis
    Home, Philip D.
    Pocock, Stuart J.
    Beck-Nielsen, Henning
    Gomis, Ramon
    Hanefeld, Markolf
    Jones, Nigel P.
    Komajda, Michel
    McMurray, John J. V.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (01) : 28 - 38
  • [23] Differences between respondents and nonrespondents in a multicenter community-based study vary by gender and ethnicity
    Jackson, R
    Chambless, LE
    Yang, K
    Byrne, T
    Watson, R
    Folsom, A
    Shahar, E
    Kalsbeek, W
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1996, 49 (12) : 1441 - 1446
  • [24] Association of hemoglobin A1c with cardiovascular disease and mortality in adults:: The European prospective investigation into cancer in Norfolk
    Khaw, KT
    Wareham, N
    Bingham, S
    Luben, R
    Welch, A
    Day, N
    [J]. ANNALS OF INTERNAL MEDICINE, 2004, 141 (06) : 413 - 420
  • [25] Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes -: A meta-analysis
    Kirk, Julienne K.
    D'Agostino, Ralph B., Jr.
    Bell, Ronny A.
    Passmore, Leah V.
    Bonds, Denise E.
    Karter, Andrew J.
    Narayan, K. M. Venkat
    [J]. DIABETES CARE, 2006, 29 (09) : 2130 - 2136
  • [26] HbA1c measured in stored erythrocytes and mortality rate among middle-aged and older women
    Levitan, E. B.
    Liu, S.
    Stampfer, M. J.
    Cook, N. R.
    Rexrode, K. M.
    Ridker, P. M.
    Buring, J. E.
    Manson, J. E.
    [J]. DIABETOLOGIA, 2008, 51 (02) : 267 - 275
  • [27] Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study
    Meigs, JB
    Nathan, DM
    Cupples, LA
    Wilson, PWF
    Singer, DE
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1996, 49 (04) : 411 - 417
  • [28] Fasting and postchallenge glycemia and cardiovascular disease risk - The framingham offspring study
    Meigs, JB
    Nathan, DM
    D'Agostino, RB
    Wilson, PWF
    [J]. DIABETES CARE, 2002, 25 (10) : 1845 - 1850
  • [29] NAGELE U, 1984, J CLIN CHEM CLIN BIO, V22, P165
  • [30] Nissen SE, 2007, NEW ENGL J MED, V357, P100